The Gold Trade, May 24
Health Care: Drugs
Keryx Biopharmaceuticals Inc. (KERX: NASDAQ)
$8.03 0.00 | 0.00%
05/24/13 - 04:00 PM ET
TheStreet Ratings Grade for KERX
| Buy | Hold | Sell | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| A+ | A | A- | B+ | B | B- | C+ | C | C- | D+ | D | D- | E+ | E | E- | F |
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions.
Analyst Ratings
| Historical Rec | Current | 1 Mo. Ago | 2 Mo. Ago | 3 Mo. Ago |
|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 6 |
| Moderate Buy | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 |
| Moderate Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Mean Rec. | 1.00 | 1.00 | 1.00 | 1.00 |
Portfolios with KERX
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Moving Hig...
- UserBio
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- User1st Time out
Latest KERX Headlines from TheStreet
- Today's Drugs Industry Featured Laggard: Keryx Biopharmaceuticals Inc. (KERX) 04.11.13 | 05:04 pm
- Bears Eat Herbalife, JC Penney - Bulls Find Keryx
04.09.13 | 12:04 pm - Keryx Biopharmaceuticals Inc. (KERX): Health Care's Highlighted Dud Of The Day 03.26.13 | 05:03 pm
- Keryx CEO vs. A Short Seller: Zerenex Patent Debate 03.13.13 | 07:03 am
- Cramer's 'Mad Money' Recap: Next Week's Game Plan 03.08.13 | 07:03 pm
- Why Expect More Price Swings From These 4 Biotechs 02.28.13 | 11:02 am
- Keryx Biopharmaceuticals Inc. (KERX): Today's Featured Drugs Laggard 02.27.13 | 05:02 pm
- Keryx Biopharmaceuticals Inc. (KERX): Today's Featured Health Care Winner 02.12.13 | 05:02 pm
- 3 Biotech Stocks Under $10 Moving Higher 02.12.13 | 02:02 pm
- Ziopharm's Sarcoma Study And The Feuerstein-Ratain Rule 02.05.13 | 06:02 am
Press Releases for KERX
- SHAREHOLDER ALERT: Levi & Korsinsky Notifies Investors With Losses On Their Investment In Keryx Biopharmaceuticals, Inc. Of Class Action Lawsuit And The Deadline Of April 2, 2013 To Seek A Lead Plaintiff Position - Business Wire 03.25.13 | 08:03 am
- SHAREHOLDER ALERT: Levi & Korsinsky Notifies Investors With Losses On Their Investment In Keryx Biopharmaceuticals, Inc. Of Class Action Lawsuit And The Deadline Of April 2, 2013 To Seek A Lead Plaintiff Position - PR Newswire 03.19.13 | 06:03 pm
- SHAREHOLDER ALERT: Levi & Korsinsky Notifies Investors With Losses On Their Investment In Keryx Biopharmaceuticals, Inc. Of Class Action Lawsuit And The Deadline Of April 2, 2013 To Seek A Lead Plaintiff Position - Business Wire 03.18.13 | 05:03 pm
- Keryx Biopharmaceuticals To Present At The 25th Annual ROTH Conference - PR Newswire 03.14.13 | 08:03 am
- Keryx Biopharmaceuticals Announces Appointment Of Amit Sharma, M.D. As Vice President, Medical Affairs - PR Newswire 03.13.13 | 08:03 am
- Keryx Biopharmaceuticals, Inc. To Host Conference Call On Fourth Quarter And Year-End 2012 Financial Results - PR Newswire 03.11.13 | 08:03 am
- Keryx Biopharmaceuticals To Present At The Citigroup 2013 Global Healthcare Conference - PR Newswire 02.22.13 | 08:02 am
- Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Keryx Biopharmaceuticals, Inc. To Contact The Firm - PR Newswire 02.08.13 | 09:02 pm
- Harwood Feffer LLP Announces Investigation Of Keryx Biopharmaceuticals, Inc. - PR Newswire 02.08.13 | 12:02 pm
- Keryx Biopharmaceuticals To Present At The 15th Annual BIO CEO & Investor Conference Presentation Scheduled For Monday, February 11th At 2:30 PM ET - PR Newswire 02.08.13 | 08:02 am
Partner Headlines for KERX
- Zerenex Phase III Data Imminent; Odds Still High For Keryx To Succeed With This Drug - Seeking Alpha 01.22.13 | 09:01 am
- Dawson James Securities Reiterates Market Outperform Rating, $4 PT on Keryx Biopharmaceuticals - Benzinga 11.28.12 | 09:11 am
- Healthcare Biz Roundup: Keryx Jumps Without CAUSE, Teva Not A MONOPOLIST - Wall St. Cheat Sheet 07.04.12 | 08:07 am
- Zacks' Voice of the People highlights opportunities with Starbucks, Realty Income, Keryx Biopharma, Bon-Ton Stores and Orexigen Therapeutics - Press Releases - Zacks 04.12.12 | 09:04 am
- 2 Biotech Stocks To Consider Now, 1 To Avoid - Seeking Alpha 04.10.12 | 09:04 am
- Stocks To Watch: Week Of March 19-23 - Seeking Alpha 03.21.12 | 08:03 am
- VIX - Options Volatility Sonar: Friday Recap - Seeking Alpha 03.16.12 | 05:03 pm
- Morning Social Media Outlook for Tuesday Mar 6 (SHFL, HAR, PCX, NTRI) - Benzinga 03.06.12 | 09:03 am
- FDA Approval Practically A Done Deal For Keryx And AEterna Zentaris - Seeking Alpha 03.02.12 | 05:03 pm
- 3 Boring Dividend Stocks You Will Grow To Love - Seeking Alpha 02.26.12 | 07:02 am
